Caffa et al. report in Nature that hormone-receptor-positive breast cancer is sensitive to a form of ‘dietary augmentation therapy’ that implements periods of fasting, thus enhancing anti-cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Caffa, I. et al. Nature https://doi.org/10.1038/s41586-020-2502-7 (2020).
Eliassen, A. H., Colditz, G. A., Rosner, B., Willett, W. C. & Hankinson, S. E. J. Am. Med. Assoc. 296, 193–201 (2006).
Kroenke, C. H., Chen, W. Y., Rosner, B. & Holmes, M. D. J. Clin. Oncol. 23, 1370–1378 (2005).
Tamimi, R. M. et al. Am. J. Epidemiol. 184, 884–893 (2016).
Hopkins, B. D., Goncalves, M. D. & Cantley, L. C. J. Clin. Oncol. 34, 4277–4283 (2016).
Schild, T., Low, V., Blenis, J. & Gomes, A. P. Cancer Cell 33, 347–354 (2018).
Commisso, C. et al. Nature 497, 633–637 (2013).
Yun, J. et al. Science 325, 1555–1559 (2009).
Brandhorst, S. et al. Cell Metab. 22, 86–99 (2015).
Patterson, R. E. & Sears, D. D. Annu. Rev. Nutr. 37, 371–393 (2017).
Chlebowski, R. T. et al. J. Clin. Oncol. 35, 2919–2926 (2017).
Hopkins, B. D. et al. Nature 560, 499–503 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.C.C. is a founder, shareholder and member of the BOD and SAB of Agios Pharmaceuticals. He is also a cofounder and member of the SAB and a shareholder of Petra Pharmaceuticals. Both companies are developing therapies for cancer. The laboratory of L.C.C. also receives financial support from Petra Pharmaceuticals. L.C.C. and M.D.G. are cofounders and shareholders of Faeth Therapeutics, which is developing nutritional therapies for cancer. M.D.G. has received speaking and/or consulting fees from Pfizer Inc., Bayer AG, Novartis AG, Petra Pharmaceuticals and TruMacro nutrition. The laboratory of M.D.G. receives financial support from Pfizer, Inc.
Rights and permissions
About this article
Cite this article
Goncalves, M.D., Cantley, L.C. A ‘fast’er way to treat breast cancer. Nat Metab 2, 559–560 (2020). https://doi.org/10.1038/s42255-020-0225-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-020-0225-6
